Nasdaq Itci News Today

Mach 1 Financial Group LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $514,000. Several other hedge funds and other institutional investors […]

Mach 1 Financial Group LLC bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,180 shares of the biopharmaceutical company’s stock, valued at approximately $514,000. A number of […]

Several analysts have recently updated their ratings and price targets for Intra-Cellular Therapies (NASDAQ: ITCI): 4/24/2024 – Intra-Cellular Therapies had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock. 4/23/2024 – Intra-Cellular Therapies had its price target raised by analysts at Canaccord Genuity Group Inc. […]

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 36.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,738 shares of the biopharmaceutical company’s stock after acquiring an additional 4,974 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, Benzinga reports. They presently have a $120.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 66.37% from the stock’s […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its target price upped by Mizuho from $82.00 to $96.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price objective points to a potential upside of 29.71% from the stock’s previous close. […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its price objective hoisted by equities research analysts at Mizuho from $82.00 to $96.00 in a report released on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price suggests a potential upside of 29.71% from the company’s previous […]

Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price objective boosted by Canaccord Genuity Group from $100.00 to $107.00 in a report released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Robert W. Baird increased […]

Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) had its price target hoisted by Robert W. Baird from $83.00 to $103.00 in a report issued on Wednesday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. Several other equities analysts have also weighed in on the company. The Goldman Sachs Group lifted their […]

Strs Ohio decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 5.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,300 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the quarter. Strs Ohio’s holdings in Intra-Cellular […]